Mandate

Vinge has advised Apotea in connection with its listing on Nasdaq Stockholm

Vinge has advised Apotea AB (publ) (“Apotea”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on November 26, 2024 and the first day of trading is December 6, 2024.

The offering price was SEK 58 per ordinary share, corresponding to a total market value for all ordinary shares in Apotea of approximately SEK 6 billion. The total value of the offering amounts to approximately SEK 1,880 million, provided that the overallotment option is exercised in full.

Apotea is Sweden’s leading online pharmacy by market share with the goal of becoming the largest pharmacy in Sweden and hence also in the Nordics. With the widest assortment on the market, low prices and quick deliveries, the company facilitates everyday life for its three million active customers.

Vinge’s team primarily consisted of Jesper Schönbeck, Amanda Knutsson, Anna Svensson, Lorin Arabi, Karin Karsten and Elias Kröger (Capital Markets and Public M&A), Victor Ericsson, Emelie Svanberg, Ellenor Eckerborn och Marcus Svärd (Corporate Tax), Sam Seddigh and Emil Lindwall (Employment), Helena Rosén Andersson and Hilda Ivarsson (Permits), Fredrika Hjelmberg, Mario Saad and Siri Blomberg (Commercial agreements, IT and GDPR), Ian Jonson (Intellectual Property) and Sofia Haggren (Financing).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025